Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | GHSR | Q92847 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2629153 | 1.00 | CYP2C9 (0.53) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL2629152 | 0.90 | CYP2C9 (0.52) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL1763513 | 0.90 | CYP2C9 (0.52) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL2633281 | 0.89 | CYP2C9 (0.55) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL2628970 | 0.89 | CYP2C9 (0.55) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL12151959 | 0.86 | CYP2D6 (0.58) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL12151987 | 0.86 | CYP2D6 (0.58) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL1763143 | 0.85 | CYP2C19 (0.53) | CYP2C9CYP2D6CYP3A4CYP2C19GHSR | |
| SCHEMBL2633400 | 0.85 | CYP2C9 (0.57) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL2629150 | 0.85 | CYP2C9 (0.57) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238583-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
| US-20120095017-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| US-20110118279-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238583-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CYP2C9 1267/4885CYP2D6 600/4885CYP3A4 224/4885 |
| US-20120095017-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CYP2C9 1267/4885CYP2D6 600/4885CYP3A4 224/4885 |
| US-20110118279-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CYP2C9 1267/4885CYP2D6 600/4885CYP3A4 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.